BioGeneration Ventures Leads Europe's Seed Investing With New Fund

A new VC fund raised by the Netherlands firm, BioGeneration Ventures, has attracted pharma corporate and private investors and is now one of the largest-ever funds focused on making seed investments in European biotech companies.

Naarden
The historic town hall in Naarden • Source: Shutterstock

The Naarden, Netherlands-based venture capital company, BioGeneration Ventures (BGV), has raised €82m at the final close of its third fund, BGV III, to provide seed investments to European biotech companies involved in developing therapeutics, medical devices and diagnostics, particularly those based in the Benelux countries – Belgium, the Netherlands and Luxembourg – and in Germany.

The fund is four times larger than previous funds raised by BGV (€17m in 2006 and €15m in 2012), and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.